查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1867612

病毒载体和质体DNA生产：全球市场份额和排名、总收入和需求预测（2025-2031年）

Viral Vectors and Plasmid DNA Manufacturing - Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
出版日期: | 出版商: QYResearch | 英文 111 Pages | 商品交期: 2-3个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2024 年全球病毒载体和质体DNA 生产市场规模估计为 6.68 亿美元，预计到 2031 年将达到 45.11 亿美元，在预测期（2025-2031 年）内以 31.8% 的复合年增长率增长。

病毒载体和质体DNA的生产是基因和细胞治疗价值链中的关键平台技术，能够实现治疗基因的传递和表现。病毒载体，如腺相关病毒（AAV）、腺病毒和慢病毒，因其高效的基因转移能力，成为CAR-T疗法、基因编辑平台和疫苗研发的基础。质体DNA是重要的上游工程加工组分，支持病毒载体的生产、mRNA的合成和DNA疫苗的研发。随着基因和细胞疗法走向大规模商业化，符合GMP标准的病毒载体和质体DNA生产能力已成为生物製药公司、合约研发生产机构（CDMO）平台和全球投资者的策略关注点。

随着基因和细胞疗法在全球范围内获得监管部门的核准，对病毒载体和质体DNA工业化生产的需求正在迅速增长。重磅CAR-T产品、AAV基因疗法和mRNA疫苗的持续扩大规模，推动了对符合GMP规范的平台、健全的品质系统和高纯度原料的需求。为了配合製药公司「轻资产」策略，合约研发生产机构（CDMO）在产业升级中发挥关键作用。各国政府也正在透过策略性资金支持、基础建设和旨在实现在地化、模组化和自动化的政策倡议，促进生物製造能力的发展。该行业面临着许多技术和营运方面的挑战，包括高昂的生产成本、缺乏标准化流程以及严格的品管难题。高纯度质体製备和高效病毒载体生产，特别是杂质去除和产量优化，仍然是关键瓶颈。各地区的法规结构正在快速变化，要求製造商应对不同的GMP合规要求和更严格的核准标准。此外，顶级CDMO产能的集中加剧了竞争和价格压力，提高了新兴企业的市场进入门槛。下游市场正从学术实验室和早期生技公司转向商业化阶段的生物製药公司，订单量也从克级成长到公斤级。 AAV、LNP-mRNA和CAR-T疗法的研发管线高度依赖客製化病毒载体和高品质质体。罕见疾病、肿瘤和疫苗的研发推动了对具有更高表达水平、更低免疫抗原性和更安全可控的递送工具的需求。这促使人们开发可扩展的模组化GMP生产系统，以满足精确的特定应用需求。

本报告旨在按地区/国家、类型和应用对全球病毒载体和质体DNA生产市场进行全面分析，重点关注总收入、市场份额和主要企业的排名。

病毒载体和质体DNA生产市场规模、估计值和预测均以销售收入为指标，以2024年为基准年，并包含2020年至2031年的历史数据和预测数据。报告采用定量和定性分析相结合的方法，帮助读者制定业务/成长策略、评估市场竞争、分析自身在当前市场中的地位，并就病毒载体和质体DNA生产做出明智的商业决策。

市场区隔

公司

  • Thermo Fisher Scientific
  • Lonza
  • Azenta Life Sciences
  • Revvity
  • VectorBuilder
  • Takara Bio
  • GenScript Biotech
  • Gene Chem
  • Geno Meditech
  • PackGene Biotech
  • VIROVEK
  • OriGen
  • Vector BioLabs

按类型分類的细分市场

  • AAV
  • 慢病毒
  • 逆转录病毒
  • 腺病毒
  • DNA质体
  • 其他的

应用领域

  • 製药和生物製药公司
  • 学术和研究机构

按地区

  • 北美洲
    • 美国
    • 加拿大
  • 亚太地区
    • 中国
    • 日本
    • 韩国
    • 东南亚
    • 印度
    • 澳洲
    • 亚太其他地区
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 义大利
    • 荷兰
    • 北欧国家
    • 其他欧洲
  • 拉丁美洲
    • 墨西哥
    • 巴西
    • 其他拉丁美洲
  • 中东和非洲
    • 土耳其
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 其他中东和非洲地区

The global market for Viral Vectors and Plasmid DNA Manufacturing was estimated to be worth US$ 668 million in 2024 and is forecast to a readjusted size of US$ 4511 million by 2031 with a CAGR of 31.8% during the forecast period 2025-2031.

Viral vectors and plasmid DNA manufacturing represent essential infrastructure in the gene and cell therapy value chain, enabling the delivery and expression of therapeutic genes. Viral vectors-including AAV, adenovirus, and lentivirus-are foundational to CAR-T therapies, gene editing platforms, and vaccine development due to their efficient gene transfer capabilities. Plasmid DNA, as a crucial upstream component, supports viral vector production, mRNA synthesis, and DNA vaccine development. As gene and cell therapies move toward large-scale commercialization, GMP-grade manufacturing capacity of viral vectors and plasmid DNA has become a strategic focal point for biopharma companies, CDMO platforms, and global investors.

As gene and cell therapies gain global regulatory approvals, demand for industrial-scale manufacturing of viral vectors and plasmid DNA is rapidly expanding. Blockbuster CAR-T products, AAV gene therapies, and mRNA vaccines continue to scale up, fueling the need for GMP-compliant platforms, robust quality systems, and high-purity raw materials. CDMO players are becoming the core force in industrial upgrading under the "asset-light" strategies of pharmaceutical companies. Governments worldwide are also promoting bio-manufacturing capacity through strategic funding, infrastructure support, and policy initiatives aimed at localization, modularity, and automation. The industry faces significant technical and operational barriers, including high production costs, lack of standardized processes, and stringent quality control challenges. Key bottlenecks persist in high-purity plasmid preparation and efficient viral vector production, particularly in impurity removal and yield optimization. Regulatory frameworks are evolving rapidly across different regions, requiring manufacturers to navigate diverse GMP compliance requirements and stricter approval thresholds. Additionally, the high concentration of capacity among top-tier CDMOs intensifies competition and pricing pressure, raising the market entry threshold for emerging players. The downstream market is transitioning from academic labs and early-stage biotech firms to commercial-stage biopharmaceutical companies, with order volumes scaling from grams to kilograms. AAV, LNP-mRNA, and CAR-T pipelines heavily rely on customized viral vectors and high-quality plasmids. In rare diseases, oncology, and vaccine development, demand is rising for delivery tools with enhanced expression, reduced immunogenicity, and controlled safety. This is driving the construction of scalable, modular GMP manufacturing systems that can meet precise, application-specific requirements.

This report aims to provide a comprehensive presentation of the global market for Viral Vectors and Plasmid DNA Manufacturing, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Viral Vectors and Plasmid DNA Manufacturing by region & country, by Type, and by Application.

The Viral Vectors and Plasmid DNA Manufacturing market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Viral Vectors and Plasmid DNA Manufacturing.

Market Segmentation

By Company

  • Thermo Fisher Scientific
  • Lonza
  • Azenta Life Sciences
  • Revvity
  • VectorBuilder
  • Takara Bio
  • GenScript Biotech
  • Gene Chem
  • Geno Meditech
  • PackGene Biotech
  • VIROVEK
  • OriGen
  • Vector BioLabs

Segment by Type

  • AAV
  • Lentiviruses
  • Retroviruses
  • Adenoviruses
  • DNA Plasmids
  • Other

Segment by Application

  • Pharmaceutical and Biopharmaceutical Companies
  • Academics and Research Institutes

By Region

  • North America
    • United States
    • Canada
  • Asia-Pacific
    • China
    • Japan
    • South Korea
    • Southeast Asia
    • India
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • U.K.
    • Italy
    • Netherlands
    • Nordic Countries
    • Rest of Europe
  • Latin America
    • Mexico
    • Brazil
    • Rest of Latin America
  • Middle East & Africa
    • Turkey
    • Saudi Arabia
    • UAE
    • Rest of MEA

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 2: Detailed analysis of Viral Vectors and Plasmid DNA Manufacturing company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 5: Revenue of Viral Vectors and Plasmid DNA Manufacturing in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 6: Revenue of Viral Vectors and Plasmid DNA Manufacturing in country level. It provides sigmate data by Type, and by Application for each country/region.

Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.

Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 9: Conclusion.

Table of Contents

1 Market Overview

  • 1.1 Viral Vectors and Plasmid DNA Manufacturing Product Introduction
  • 1.2 Global Viral Vectors and Plasmid DNA Manufacturing Market Size Forecast (2020-2031)
  • 1.3 Viral Vectors and Plasmid DNA Manufacturing Market Trends & Drivers
    • 1.3.1 Viral Vectors and Plasmid DNA Manufacturing Industry Trends
    • 1.3.2 Viral Vectors and Plasmid DNA Manufacturing Market Drivers & Opportunity
    • 1.3.3 Viral Vectors and Plasmid DNA Manufacturing Market Challenges
    • 1.3.4 Viral Vectors and Plasmid DNA Manufacturing Market Restraints
  • 1.4 Assumptions and Limitations
  • 1.5 Study Objectives
  • 1.6 Years Considered

2 Competitive Analysis by Company

  • 2.1 Global Viral Vectors and Plasmid DNA Manufacturing Players Revenue Ranking (2024)
  • 2.2 Global Viral Vectors and Plasmid DNA Manufacturing Revenue by Company (2020-2025)
  • 2.3 Key Companies Viral Vectors and Plasmid DNA Manufacturing Manufacturing Base Distribution and Headquarters
  • 2.4 Key Companies Viral Vectors and Plasmid DNA Manufacturing Product Offered
  • 2.5 Key Companies Time to Begin Mass Production of Viral Vectors and Plasmid DNA Manufacturing
  • 2.6 Viral Vectors and Plasmid DNA Manufacturing Market Competitive Analysis
    • 2.6.1 Viral Vectors and Plasmid DNA Manufacturing Market Concentration Rate (2020-2025)
    • 2.6.2 Global 5 and 10 Largest Companies by Viral Vectors and Plasmid DNA Manufacturing Revenue in 2024
    • 2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Viral Vectors and Plasmid DNA Manufacturing as of 2024)
  • 2.7 Mergers & Acquisitions, Expansion

3 Segmentation by Type

  • 3.1 Introduction by Type
    • 3.1.1 AAV
    • 3.1.2 Lentiviruses
    • 3.1.3 Retroviruses
    • 3.1.4 Adenoviruses
    • 3.1.5 DNA Plasmids
    • 3.1.6 Other
  • 3.2 Global Viral Vectors and Plasmid DNA Manufacturing Sales Value by Type
    • 3.2.1 Global Viral Vectors and Plasmid DNA Manufacturing Sales Value by Type (2020 VS 2024 VS 2031)
    • 3.2.2 Global Viral Vectors and Plasmid DNA Manufacturing Sales Value, by Type (2020-2031)
    • 3.2.3 Global Viral Vectors and Plasmid DNA Manufacturing Sales Value, by Type (%) (2020-2031)

4 Segmentation by Application

  • 4.1 Introduction by Application
    • 4.1.1 Pharmaceutical and Biopharmaceutical Companies
    • 4.1.2 Academics and Research Institutes
  • 4.2 Global Viral Vectors and Plasmid DNA Manufacturing Sales Value by Application
    • 4.2.1 Global Viral Vectors and Plasmid DNA Manufacturing Sales Value by Application (2020 VS 2024 VS 2031)
    • 4.2.2 Global Viral Vectors and Plasmid DNA Manufacturing Sales Value, by Application (2020-2031)
    • 4.2.3 Global Viral Vectors and Plasmid DNA Manufacturing Sales Value, by Application (%) (2020-2031)

5 Segmentation by Region

  • 5.1 Global Viral Vectors and Plasmid DNA Manufacturing Sales Value by Region
    • 5.1.1 Global Viral Vectors and Plasmid DNA Manufacturing Sales Value by Region: 2020 VS 2024 VS 2031
    • 5.1.2 Global Viral Vectors and Plasmid DNA Manufacturing Sales Value by Region (2020-2025)
    • 5.1.3 Global Viral Vectors and Plasmid DNA Manufacturing Sales Value by Region (2026-2031)
    • 5.1.4 Global Viral Vectors and Plasmid DNA Manufacturing Sales Value by Region (%), (2020-2031)
  • 5.2 North America
    • 5.2.1 North America Viral Vectors and Plasmid DNA Manufacturing Sales Value, 2020-2031
    • 5.2.2 North America Viral Vectors and Plasmid DNA Manufacturing Sales Value by Country (%), 2024 VS 2031
  • 5.3 Europe
    • 5.3.1 Europe Viral Vectors and Plasmid DNA Manufacturing Sales Value, 2020-2031
    • 5.3.2 Europe Viral Vectors and Plasmid DNA Manufacturing Sales Value by Country (%), 2024 VS 2031
  • 5.4 Asia Pacific
    • 5.4.1 Asia Pacific Viral Vectors and Plasmid DNA Manufacturing Sales Value, 2020-2031
    • 5.4.2 Asia Pacific Viral Vectors and Plasmid DNA Manufacturing Sales Value by Region (%), 2024 VS 2031
  • 5.5 South America
    • 5.5.1 South America Viral Vectors and Plasmid DNA Manufacturing Sales Value, 2020-2031
    • 5.5.2 South America Viral Vectors and Plasmid DNA Manufacturing Sales Value by Country (%), 2024 VS 2031
  • 5.6 Middle East & Africa
    • 5.6.1 Middle East & Africa Viral Vectors and Plasmid DNA Manufacturing Sales Value, 2020-2031
    • 5.6.2 Middle East & Africa Viral Vectors and Plasmid DNA Manufacturing Sales Value by Country (%), 2024 VS 2031

6 Segmentation by Key Countries/Regions

  • 6.1 Key Countries/Regions Viral Vectors and Plasmid DNA Manufacturing Sales Value Growth Trends, 2020 VS 2024 VS 2031
  • 6.2 Key Countries/Regions Viral Vectors and Plasmid DNA Manufacturing Sales Value, 2020-2031
  • 6.3 United States
    • 6.3.1 United States Viral Vectors and Plasmid DNA Manufacturing Sales Value, 2020-2031
    • 6.3.2 United States Viral Vectors and Plasmid DNA Manufacturing Sales Value by Type (%), 2024 VS 2031
    • 6.3.3 United States Viral Vectors and Plasmid DNA Manufacturing Sales Value by Application, 2024 VS 2031
  • 6.4 Europe
    • 6.4.1 Europe Viral Vectors and Plasmid DNA Manufacturing Sales Value, 2020-2031
    • 6.4.2 Europe Viral Vectors and Plasmid DNA Manufacturing Sales Value by Type (%), 2024 VS 2031
    • 6.4.3 Europe Viral Vectors and Plasmid DNA Manufacturing Sales Value by Application, 2024 VS 2031
  • 6.5 China
    • 6.5.1 China Viral Vectors and Plasmid DNA Manufacturing Sales Value, 2020-2031
    • 6.5.2 China Viral Vectors and Plasmid DNA Manufacturing Sales Value by Type (%), 2024 VS 2031
    • 6.5.3 China Viral Vectors and Plasmid DNA Manufacturing Sales Value by Application, 2024 VS 2031
  • 6.6 Japan
    • 6.6.1 Japan Viral Vectors and Plasmid DNA Manufacturing Sales Value, 2020-2031
    • 6.6.2 Japan Viral Vectors and Plasmid DNA Manufacturing Sales Value by Type (%), 2024 VS 2031
    • 6.6.3 Japan Viral Vectors and Plasmid DNA Manufacturing Sales Value by Application, 2024 VS 2031
  • 6.7 South Korea
    • 6.7.1 South Korea Viral Vectors and Plasmid DNA Manufacturing Sales Value, 2020-2031
    • 6.7.2 South Korea Viral Vectors and Plasmid DNA Manufacturing Sales Value by Type (%), 2024 VS 2031
    • 6.7.3 South Korea Viral Vectors and Plasmid DNA Manufacturing Sales Value by Application, 2024 VS 2031
  • 6.8 Southeast Asia
    • 6.8.1 Southeast Asia Viral Vectors and Plasmid DNA Manufacturing Sales Value, 2020-2031
    • 6.8.2 Southeast Asia Viral Vectors and Plasmid DNA Manufacturing Sales Value by Type (%), 2024 VS 2031
    • 6.8.3 Southeast Asia Viral Vectors and Plasmid DNA Manufacturing Sales Value by Application, 2024 VS 2031
  • 6.9 India
    • 6.9.1 India Viral Vectors and Plasmid DNA Manufacturing Sales Value, 2020-2031
    • 6.9.2 India Viral Vectors and Plasmid DNA Manufacturing Sales Value by Type (%), 2024 VS 2031
    • 6.9.3 India Viral Vectors and Plasmid DNA Manufacturing Sales Value by Application, 2024 VS 2031

7 Company Profiles

  • 7.1 Thermo Fisher Scientific
    • 7.1.1 Thermo Fisher Scientific Profile
    • 7.1.2 Thermo Fisher Scientific Main Business
    • 7.1.3 Thermo Fisher Scientific Viral Vectors and Plasmid DNA Manufacturing Products, Services and Solutions
    • 7.1.4 Thermo Fisher Scientific Viral Vectors and Plasmid DNA Manufacturing Revenue (US$ Million) & (2020-2025)
    • 7.1.5 Thermo Fisher Scientific Recent Developments
  • 7.2 Lonza
    • 7.2.1 Lonza Profile
    • 7.2.2 Lonza Main Business
    • 7.2.3 Lonza Viral Vectors and Plasmid DNA Manufacturing Products, Services and Solutions
    • 7.2.4 Lonza Viral Vectors and Plasmid DNA Manufacturing Revenue (US$ Million) & (2020-2025)
    • 7.2.5 Lonza Recent Developments
  • 7.3 Azenta Life Sciences
    • 7.3.1 Azenta Life Sciences Profile
    • 7.3.2 Azenta Life Sciences Main Business
    • 7.3.3 Azenta Life Sciences Viral Vectors and Plasmid DNA Manufacturing Products, Services and Solutions
    • 7.3.4 Azenta Life Sciences Viral Vectors and Plasmid DNA Manufacturing Revenue (US$ Million) & (2020-2025)
    • 7.3.5 Azenta Life Sciences Recent Developments
  • 7.4 Revvity
    • 7.4.1 Revvity Profile
    • 7.4.2 Revvity Main Business
    • 7.4.3 Revvity Viral Vectors and Plasmid DNA Manufacturing Products, Services and Solutions
    • 7.4.4 Revvity Viral Vectors and Plasmid DNA Manufacturing Revenue (US$ Million) & (2020-2025)
    • 7.4.5 Revvity Recent Developments
  • 7.5 VectorBuilder
    • 7.5.1 VectorBuilder Profile
    • 7.5.2 VectorBuilder Main Business
    • 7.5.3 VectorBuilder Viral Vectors and Plasmid DNA Manufacturing Products, Services and Solutions
    • 7.5.4 VectorBuilder Viral Vectors and Plasmid DNA Manufacturing Revenue (US$ Million) & (2020-2025)
    • 7.5.5 VectorBuilder Recent Developments
  • 7.6 Takara Bio
    • 7.6.1 Takara Bio Profile
    • 7.6.2 Takara Bio Main Business
    • 7.6.3 Takara Bio Viral Vectors and Plasmid DNA Manufacturing Products, Services and Solutions
    • 7.6.4 Takara Bio Viral Vectors and Plasmid DNA Manufacturing Revenue (US$ Million) & (2020-2025)
    • 7.6.5 Takara Bio Recent Developments
  • 7.7 GenScript Biotech
    • 7.7.1 GenScript Biotech Profile
    • 7.7.2 GenScript Biotech Main Business
    • 7.7.3 GenScript Biotech Viral Vectors and Plasmid DNA Manufacturing Products, Services and Solutions
    • 7.7.4 GenScript Biotech Viral Vectors and Plasmid DNA Manufacturing Revenue (US$ Million) & (2020-2025)
    • 7.7.5 GenScript Biotech Recent Developments
  • 7.8 Gene Chem
    • 7.8.1 Gene Chem Profile
    • 7.8.2 Gene Chem Main Business
    • 7.8.3 Gene Chem Viral Vectors and Plasmid DNA Manufacturing Products, Services and Solutions
    • 7.8.4 Gene Chem Viral Vectors and Plasmid DNA Manufacturing Revenue (US$ Million) & (2020-2025)
    • 7.8.5 Gene Chem Recent Developments
  • 7.9 Geno Meditech
    • 7.9.1 Geno Meditech Profile
    • 7.9.2 Geno Meditech Main Business
    • 7.9.3 Geno Meditech Viral Vectors and Plasmid DNA Manufacturing Products, Services and Solutions
    • 7.9.4 Geno Meditech Viral Vectors and Plasmid DNA Manufacturing Revenue (US$ Million) & (2020-2025)
    • 7.9.5 Geno Meditech Recent Developments
  • 7.10 PackGene Biotech
    • 7.10.1 PackGene Biotech Profile
    • 7.10.2 PackGene Biotech Main Business
    • 7.10.3 PackGene Biotech Viral Vectors and Plasmid DNA Manufacturing Products, Services and Solutions
    • 7.10.4 PackGene Biotech Viral Vectors and Plasmid DNA Manufacturing Revenue (US$ Million) & (2020-2025)
    • 7.10.5 PackGene Biotech Recent Developments
  • 7.11 VIROVEK
    • 7.11.1 VIROVEK Profile
    • 7.11.2 VIROVEK Main Business
    • 7.11.3 VIROVEK Viral Vectors and Plasmid DNA Manufacturing Products, Services and Solutions
    • 7.11.4 VIROVEK Viral Vectors and Plasmid DNA Manufacturing Revenue (US$ Million) & (2020-2025)
    • 7.11.5 VIROVEK Recent Developments
  • 7.12 OriGen
    • 7.12.1 OriGen Profile
    • 7.12.2 OriGen Main Business
    • 7.12.3 OriGen Viral Vectors and Plasmid DNA Manufacturing Products, Services and Solutions
    • 7.12.4 OriGen Viral Vectors and Plasmid DNA Manufacturing Revenue (US$ Million) & (2020-2025)
    • 7.12.5 OriGen Recent Developments
  • 7.13 Vector BioLabs
    • 7.13.1 Vector BioLabs Profile
    • 7.13.2 Vector BioLabs Main Business
    • 7.13.3 Vector BioLabs Viral Vectors and Plasmid DNA Manufacturing Products, Services and Solutions
    • 7.13.4 Vector BioLabs Viral Vectors and Plasmid DNA Manufacturing Revenue (US$ Million) & (2020-2025)
    • 7.13.5 Vector BioLabs Recent Developments

8 Industry Chain Analysis

  • 8.1 Viral Vectors and Plasmid DNA Manufacturing Industrial Chain
  • 8.2 Viral Vectors and Plasmid DNA Manufacturing Upstream Analysis
    • 8.2.1 Key Raw Materials
    • 8.2.2 Raw Materials Key Suppliers
    • 8.2.3 Manufacturing Cost Structure
  • 8.3 Midstream Analysis
  • 8.4 Downstream Analysis (Customers Analysis)
  • 8.5 Sales Model and Sales Channels
    • 8.5.1 Viral Vectors and Plasmid DNA Manufacturing Sales Model
    • 8.5.2 Sales Channel
    • 8.5.3 Viral Vectors and Plasmid DNA Manufacturing Distributors

9 Research Findings and Conclusion

10 Appendix

  • 10.1 Research Methodology
    • 10.1.1 Methodology/Research Approach
      • 10.1.1.1 Research Programs/Design
      • 10.1.1.2 Market Size Estimation
      • 10.1.1.3 Market Breakdown and Data Triangulation
    • 10.1.2 Data Source
      • 10.1.2.1 Secondary Sources
      • 10.1.2.2 Primary Sources
  • 10.2 Author Details
  • 10.3 Disclaimer

List of Tables

  • Table 1. Viral Vectors and Plasmid DNA Manufacturing Market Trends
  • Table 2. Viral Vectors and Plasmid DNA Manufacturing Market Drivers & Opportunity
  • Table 3. Viral Vectors and Plasmid DNA Manufacturing Market Challenges
  • Table 4. Viral Vectors and Plasmid DNA Manufacturing Market Restraints
  • Table 5. Global Viral Vectors and Plasmid DNA Manufacturing Revenue by Company (2020-2025) & (US$ Million)
  • Table 6. Global Viral Vectors and Plasmid DNA Manufacturing Revenue Market Share by Company (2020-2025)
  • Table 7. Key Companies Viral Vectors and Plasmid DNA Manufacturing Manufacturing Base Distribution and Headquarters
  • Table 8. Key Companies Viral Vectors and Plasmid DNA Manufacturing Product Type
  • Table 9. Key Companies Time to Begin Mass Production of Viral Vectors and Plasmid DNA Manufacturing
  • Table 10. Global Viral Vectors and Plasmid DNA Manufacturing Companies Market Concentration Ratio (CR5 and HHI)
  • Table 11. Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Viral Vectors and Plasmid DNA Manufacturing as of 2024)
  • Table 12. Mergers & Acquisitions, Expansion Plans
  • Table 13. Global Viral Vectors and Plasmid DNA Manufacturing Sales Value by Type: 2020 VS 2024 VS 2031 (US$ Million)
  • Table 14. Global Viral Vectors and Plasmid DNA Manufacturing Sales Value by Type (2020-2025) & (US$ Million)
  • Table 15. Global Viral Vectors and Plasmid DNA Manufacturing Sales Value by Type (2026-2031) & (US$ Million)
  • Table 16. Global Viral Vectors and Plasmid DNA Manufacturing Sales Market Share in Value by Type (2020-2025)
  • Table 17. Global Viral Vectors and Plasmid DNA Manufacturing Sales Market Share in Value by Type (2026-2031)
  • Table 18. Global Viral Vectors and Plasmid DNA Manufacturing Sales Value by Application: 2020 VS 2024 VS 2031 (US$ Million)
  • Table 19. Global Viral Vectors and Plasmid DNA Manufacturing Sales Value by Application (2020-2025) & (US$ Million)
  • Table 20. Global Viral Vectors and Plasmid DNA Manufacturing Sales Value by Application (2026-2031) & (US$ Million)
  • Table 21. Global Viral Vectors and Plasmid DNA Manufacturing Sales Market Share in Value by Application (2020-2025)
  • Table 22. Global Viral Vectors and Plasmid DNA Manufacturing Sales Market Share in Value by Application (2026-2031)
  • Table 23. Global Viral Vectors and Plasmid DNA Manufacturing Sales Value by Region, (2020 VS 2024 VS 2031) & (US$ Million)
  • Table 24. Global Viral Vectors and Plasmid DNA Manufacturing Sales Value by Region (2020-2025) & (US$ Million)
  • Table 25. Global Viral Vectors and Plasmid DNA Manufacturing Sales Value by Region (2026-2031) & (US$ Million)
  • Table 26. Global Viral Vectors and Plasmid DNA Manufacturing Sales Value by Region (2020-2025) & (%)
  • Table 27. Global Viral Vectors and Plasmid DNA Manufacturing Sales Value by Region (2026-2031) & (%)
  • Table 28. Key Countries/Regions Viral Vectors and Plasmid DNA Manufacturing Sales Value Growth Trends, (US$ Million): 2020 VS 2024 VS 2031
  • Table 29. Key Countries/Regions Viral Vectors and Plasmid DNA Manufacturing Sales Value, (2020-2025) & (US$ Million)
  • Table 30. Key Countries/Regions Viral Vectors and Plasmid DNA Manufacturing Sales Value, (2026-2031) & (US$ Million)
  • Table 31. Thermo Fisher Scientific Basic Information List
  • Table 32. Thermo Fisher Scientific Description and Business Overview
  • Table 33. Thermo Fisher Scientific Viral Vectors and Plasmid DNA Manufacturing Products, Services and Solutions
  • Table 34. Revenue (US$ Million) in Viral Vectors and Plasmid DNA Manufacturing Business of Thermo Fisher Scientific (2020-2025)
  • Table 35. Thermo Fisher Scientific Recent Developments
  • Table 36. Lonza Basic Information List
  • Table 37. Lonza Description and Business Overview
  • Table 38. Lonza Viral Vectors and Plasmid DNA Manufacturing Products, Services and Solutions
  • Table 39. Revenue (US$ Million) in Viral Vectors and Plasmid DNA Manufacturing Business of Lonza (2020-2025)
  • Table 40. Lonza Recent Developments
  • Table 41. Azenta Life Sciences Basic Information List
  • Table 42. Azenta Life Sciences Description and Business Overview
  • Table 43. Azenta Life Sciences Viral Vectors and Plasmid DNA Manufacturing Products, Services and Solutions
  • Table 44. Revenue (US$ Million) in Viral Vectors and Plasmid DNA Manufacturing Business of Azenta Life Sciences (2020-2025)
  • Table 45. Azenta Life Sciences Recent Developments
  • Table 46. Revvity Basic Information List
  • Table 47. Revvity Description and Business Overview
  • Table 48. Revvity Viral Vectors and Plasmid DNA Manufacturing Products, Services and Solutions
  • Table 49. Revenue (US$ Million) in Viral Vectors and Plasmid DNA Manufacturing Business of Revvity (2020-2025)
  • Table 50. Revvity Recent Developments
  • Table 51. VectorBuilder Basic Information List
  • Table 52. VectorBuilder Description and Business Overview
  • Table 53. VectorBuilder Viral Vectors and Plasmid DNA Manufacturing Products, Services and Solutions
  • Table 54. Revenue (US$ Million) in Viral Vectors and Plasmid DNA Manufacturing Business of VectorBuilder (2020-2025)
  • Table 55. VectorBuilder Recent Developments
  • Table 56. Takara Bio Basic Information List
  • Table 57. Takara Bio Description and Business Overview
  • Table 58. Takara Bio Viral Vectors and Plasmid DNA Manufacturing Products, Services and Solutions
  • Table 59. Revenue (US$ Million) in Viral Vectors and Plasmid DNA Manufacturing Business of Takara Bio (2020-2025)
  • Table 60. Takara Bio Recent Developments
  • Table 61. GenScript Biotech Basic Information List
  • Table 62. GenScript Biotech Description and Business Overview
  • Table 63. GenScript Biotech Viral Vectors and Plasmid DNA Manufacturing Products, Services and Solutions
  • Table 64. Revenue (US$ Million) in Viral Vectors and Plasmid DNA Manufacturing Business of GenScript Biotech (2020-2025)
  • Table 65. GenScript Biotech Recent Developments
  • Table 66. Gene Chem Basic Information List
  • Table 67. Gene Chem Description and Business Overview
  • Table 68. Gene Chem Viral Vectors and Plasmid DNA Manufacturing Products, Services and Solutions
  • Table 69. Revenue (US$ Million) in Viral Vectors and Plasmid DNA Manufacturing Business of Gene Chem (2020-2025)
  • Table 70. Gene Chem Recent Developments
  • Table 71. Geno Meditech Basic Information List
  • Table 72. Geno Meditech Description and Business Overview
  • Table 73. Geno Meditech Viral Vectors and Plasmid DNA Manufacturing Products, Services and Solutions
  • Table 74. Revenue (US$ Million) in Viral Vectors and Plasmid DNA Manufacturing Business of Geno Meditech (2020-2025)
  • Table 75. Geno Meditech Recent Developments
  • Table 76. PackGene Biotech Basic Information List
  • Table 77. PackGene Biotech Description and Business Overview
  • Table 78. PackGene Biotech Viral Vectors and Plasmid DNA Manufacturing Products, Services and Solutions
  • Table 79. Revenue (US$ Million) in Viral Vectors and Plasmid DNA Manufacturing Business of PackGene Biotech (2020-2025)
  • Table 80. PackGene Biotech Recent Developments
  • Table 81. VIROVEK Basic Information List
  • Table 82. VIROVEK Description and Business Overview
  • Table 83. VIROVEK Viral Vectors and Plasmid DNA Manufacturing Products, Services and Solutions
  • Table 84. Revenue (US$ Million) in Viral Vectors and Plasmid DNA Manufacturing Business of VIROVEK (2020-2025)
  • Table 85. VIROVEK Recent Developments
  • Table 86. OriGen Basic Information List
  • Table 87. OriGen Description and Business Overview
  • Table 88. OriGen Viral Vectors and Plasmid DNA Manufacturing Products, Services and Solutions
  • Table 89. Revenue (US$ Million) in Viral Vectors and Plasmid DNA Manufacturing Business of OriGen (2020-2025)
  • Table 90. OriGen Recent Developments
  • Table 91. Vector BioLabs Basic Information List
  • Table 92. Vector BioLabs Description and Business Overview
  • Table 93. Vector BioLabs Viral Vectors and Plasmid DNA Manufacturing Products, Services and Solutions
  • Table 94. Revenue (US$ Million) in Viral Vectors and Plasmid DNA Manufacturing Business of Vector BioLabs (2020-2025)
  • Table 95. Vector BioLabs Recent Developments
  • Table 96. Key Raw Materials Lists
  • Table 97. Raw Materials Key Suppliers Lists
  • Table 98. Viral Vectors and Plasmid DNA Manufacturing Downstream Customers
  • Table 99. Viral Vectors and Plasmid DNA Manufacturing Distributors List
  • Table 100. Research Programs/Design for This Report
  • Table 101. Key Data Information from Secondary Sources
  • Table 102. Key Data Information from Primary Sources

List of Figures

  • Figure 1. Viral Vectors and Plasmid DNA Manufacturing Product Picture
  • Figure 2. Global Viral Vectors and Plasmid DNA Manufacturing Sales Value, 2020 VS 2024 VS 2031 (US$ Million)
  • Figure 3. Global Viral Vectors and Plasmid DNA Manufacturing Sales Value (2020-2031) & (US$ Million)
  • Figure 4. Viral Vectors and Plasmid DNA Manufacturing Report Years Considered
  • Figure 5. Global Viral Vectors and Plasmid DNA Manufacturing Players Revenue Ranking (2024) & (US$ Million)
  • Figure 6. The 5 and 10 Largest Companies in the World: Market Share by Viral Vectors and Plasmid DNA Manufacturing Revenue in 2024
  • Figure 7. Viral Vectors and Plasmid DNA Manufacturing Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
  • Figure 8. AAV Picture
  • Figure 9. Lentiviruses Picture
  • Figure 10. Retroviruses Picture
  • Figure 11. Adenoviruses Picture
  • Figure 12. DNA Plasmids Picture
  • Figure 13. Other Picture
  • Figure 14. Global Viral Vectors and Plasmid DNA Manufacturing Sales Value by Type (2020 VS 2024 VS 2031) & (US$ Million)
  • Figure 15. Global Viral Vectors and Plasmid DNA Manufacturing Sales Value Market Share by Type, 2024 & 2031
  • Figure 16. Product Picture of Pharmaceutical and Biopharmaceutical Companies
  • Figure 17. Product Picture of Academics and Research Institutes
  • Figure 18. Global Viral Vectors and Plasmid DNA Manufacturing Sales Value by Application (2020 VS 2024 VS 2031) & (US$ Million)
  • Figure 19. Global Viral Vectors and Plasmid DNA Manufacturing Sales Value Market Share by Application, 2024 & 2031
  • Figure 20. North America Viral Vectors and Plasmid DNA Manufacturing Sales Value (2020-2031) & (US$ Million)
  • Figure 21. North America Viral Vectors and Plasmid DNA Manufacturing Sales Value by Country (%), 2024 VS 2031
  • Figure 22. Europe Viral Vectors and Plasmid DNA Manufacturing Sales Value, (2020-2031) & (US$ Million)
  • Figure 23. Europe Viral Vectors and Plasmid DNA Manufacturing Sales Value by Country (%), 2024 VS 2031
  • Figure 24. Asia Pacific Viral Vectors and Plasmid DNA Manufacturing Sales Value, (2020-2031) & (US$ Million)
  • Figure 25. Asia Pacific Viral Vectors and Plasmid DNA Manufacturing Sales Value by Region (%), 2024 VS 2031
  • Figure 26. South America Viral Vectors and Plasmid DNA Manufacturing Sales Value, (2020-2031) & (US$ Million)
  • Figure 27. South America Viral Vectors and Plasmid DNA Manufacturing Sales Value by Country (%), 2024 VS 2031
  • Figure 28. Middle East & Africa Viral Vectors and Plasmid DNA Manufacturing Sales Value, (2020-2031) & (US$ Million)
  • Figure 29. Middle East & Africa Viral Vectors and Plasmid DNA Manufacturing Sales Value by Country (%), 2024 VS 2031
  • Figure 30. Key Countries/Regions Viral Vectors and Plasmid DNA Manufacturing Sales Value (%), (2020-2031)
  • Figure 31. United States Viral Vectors and Plasmid DNA Manufacturing Sales Value, (2020-2031) & (US$ Million)
  • Figure 32. United States Viral Vectors and Plasmid DNA Manufacturing Sales Value by Type (%), 2024 VS 2031
  • Figure 33. United States Viral Vectors and Plasmid DNA Manufacturing Sales Value by Application (%), 2024 VS 2031
  • Figure 34. Europe Viral Vectors and Plasmid DNA Manufacturing Sales Value, (2020-2031) & (US$ Million)
  • Figure 35. Europe Viral Vectors and Plasmid DNA Manufacturing Sales Value by Type (%), 2024 VS 2031
  • Figure 36. Europe Viral Vectors and Plasmid DNA Manufacturing Sales Value by Application (%), 2024 VS 2031
  • Figure 37. China Viral Vectors and Plasmid DNA Manufacturing Sales Value, (2020-2031) & (US$ Million)
  • Figure 38. China Viral Vectors and Plasmid DNA Manufacturing Sales Value by Type (%), 2024 VS 2031
  • Figure 39. China Viral Vectors and Plasmid DNA Manufacturing Sales Value by Application (%), 2024 VS 2031
  • Figure 40. Japan Viral Vectors and Plasmid DNA Manufacturing Sales Value, (2020-2031) & (US$ Million)
  • Figure 41. Japan Viral Vectors and Plasmid DNA Manufacturing Sales Value by Type (%), 2024 VS 2031
  • Figure 42. Japan Viral Vectors and Plasmid DNA Manufacturing Sales Value by Application (%), 2024 VS 2031
  • Figure 43. South Korea Viral Vectors and Plasmid DNA Manufacturing Sales Value, (2020-2031) & (US$ Million)
  • Figure 44. South Korea Viral Vectors and Plasmid DNA Manufacturing Sales Value by Type (%), 2024 VS 2031
  • Figure 45. South Korea Viral Vectors and Plasmid DNA Manufacturing Sales Value by Application (%), 2024 VS 2031
  • Figure 46. Southeast Asia Viral Vectors and Plasmid DNA Manufacturing Sales Value, (2020-2031) & (US$ Million)
  • Figure 47. Southeast Asia Viral Vectors and Plasmid DNA Manufacturing Sales Value by Type (%), 2024 VS 2031
  • Figure 48. Southeast Asia Viral Vectors and Plasmid DNA Manufacturing Sales Value by Application (%), 2024 VS 2031
  • Figure 49. India Viral Vectors and Plasmid DNA Manufacturing Sales Value, (2020-2031) & (US$ Million)
  • Figure 50. India Viral Vectors and Plasmid DNA Manufacturing Sales Value by Type (%), 2024 VS 2031
  • Figure 51. India Viral Vectors and Plasmid DNA Manufacturing Sales Value by Application (%), 2024 VS 2031
  • Figure 52. Viral Vectors and Plasmid DNA Manufacturing Industrial Chain
  • Figure 53. Viral Vectors and Plasmid DNA Manufacturing Manufacturing Cost Structure
  • Figure 54. Channels of Distribution (Direct Sales, and Distribution)
  • Figure 55. Bottom-up and Top-down Approaches for This Report
  • Figure 56. Data Triangulation
  • Figure 57. Key Executives Interviewed